CombiMatrix launches RNA drug discovery program

June 4, 2003 – CombiMatrix Corp. has launched a drug discovery program based on its biochip and bioinformatics technology that will focus on common viral diseases, according to a news release.

The Express Track allows for the design and preparation of siRNA molecules that could act as potential drugs. The effort is an extension of CombiMatrix’s work on synthesizing interfering RNA specific to Severe Acute Respiratory Syndrome, the release said.

CombiMatrix of Mukilteo, Wash., is an operating group of Newport Beach, Calif.-based Acacia Research Corp. CombiMatrix, which trades on Nasdaq, closed Tuesday at 2.26, up from 2.17 Monday.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.